First-in-class, potent, and selective Lactate dehydrogenase inhibitor

Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity

Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A

Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation

Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions

The first small-molecule inverse agonist for the thyroid-stimulating hormone receptor (TSHR)

TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling

Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells

Novel AMA1-RON2 Inhibitor

Novel potent inhibitor of IRAK1/4 and FLT3

Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells

Novel GPR139 receptor agonist

Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4)

Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells

Novel blocker of the interaction between FGF1 and FGFRD2 to inhibit cell proliferation, showing potent antiproliferent with less cytotoxicity.

Novel NO-donor, suppressing inflammatory and nociceptive responses

Novel HMG-CoA reductase inhibitor and nitric oxide donor

Cyanogen Bromide adduct of (R)-SCH-12679, a D1 antagonist

Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects

Novel degrader of steroid receptor co-activator 1 (SRC-1)

Novel potent and highly specific IRAK4 inhibitor

Selective water-soluble gelatinase inhibitor